2023 World Conference on Lung Cancer (Posters)-EP08.03. Nivolumab Plus Ipilimumab in Relapsed Stage III Non-small Cell Lung Cancer after Durvalumab Following Chemoradiotherapy

EP08.03. Nivolumab Plus Ipilimumab in Relapsed Stage III Non-small Cell Lung Cancer after Durvalumab Following Chemoradiotherapy - PDF(Slides)

Back to course

Pdf Summary

A study investigated the efficacy of nivolumab plus ipilimumab in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC) who had relapsed after receiving durvalumab as consolidation therapy following chemoradiotherapy (CCRT). The study aimed to determine the effectiveness of this combination therapy in patients who were not cured with durvalumab.<br /><br />The results showed that the 6-month and 12-month progression-free survival rates for nivolumab plus ipilimumab in these patients were 46.7% and 36.7%, respectively. The treatment had a long tail plateau effect, suggesting sustained benefit. It was found to be particularly effective in patients who had received durvalumab for 6 months or more.<br /><br />The study also identified factors that predicted better outcomes with this combination therapy. These factors included younger age, good performance status (ECOG-PS 0-1), PD-L1 expression of 50% or more, completion of durvalumab treatment, and longer treatment duration of durvalumab.<br /><br />The combination therapy of nivolumab plus ipilimumab has shown favorable 5-year survival rates in patients with LA-NSCLC, even in those with low PD-L1 expression. However, its clinical significance in patients who have relapsed after receiving durvalumab is still unclear.<br /><br />The study concluded that nivolumab plus ipilimumab is a feasible and effective treatment option for LA-NSCLC patients who relapse after durvalumab following CCRT. Prospective comparative trials comparing this combination therapy to cytotoxic anticancer agents, with or without PD-(L)1 therapy, are desirable to further assess its efficacy.<br /><br />This study was a retrospective analysis of patient data from multiple centers. It did not receive specific funding from any sectors. The research was approved by the Institutional Review Board of Saitama Medical University International Medical Center. The study acknowledges the potential conflicts of interest of the authors, including fees from pharmaceutical companies outside the submitted work.

Asset Subtitle

Takaaki Tokito

Meta Tag

Speaker Takaaki Tokito

Topic Local-Regional NSCLC: Novel Therapies & Trials

Keywords

nivolumab

ipilimumab

unresectable locally advanced non-small cell lung cancer

LA-NSCLC

relapse

durvalumab

chemoradiotherapy

progression-free survival rates

PD-L1 expression

combination therapy